Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of Vermont
About this trial
This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Fezolinetant
Treatment groups
32 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Vermont
Lead sponsor
University of Vermont Medical Center
Sponsor institution
Source ClinicalTrials.gov